If you are a heart patient, knowing if youre about to have a heart failure is now possible. With an endeavour to provide accurate solutions with ethical standards and care, SRL Diagnostics Limited (SRL) announced the launch of new lab test- ST2, to help identify high risk heart failure patients by measuring a specific biomarker in the bloodstream.
SRL Diagnostics is the first ever diagnostic lab in India to have launched this key medical test, available across India at all Fortis Labs/ SRL Diagnostics Labs and its collection centres for just Rs. 1600.
Speaking on the occasion, Dr.B.R.Das, President-Research & Innovation, Mentor-Molecular Pathology and Clinical Research Services, SRL Diagnostics Limited said, ST2 is the only marker available in India for accurately monitoring and predicting outcome in Heart Failure cases and SRL Diagnostics is the only service provider of this medical test in the country. Unlike many other cardiac biomarkers, ST2 correlates better with heart failure stages thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust treatment. It can reduce 30- day rehospitalisation rates by 17.3% and also reduce 30-day mortality rates by 17.6%.
Recent evidence has reported the incidence of cardiovascular disease (CVD) to be 40% to 50% higher in Asian Indians than individuals of other ethnic origins. In addition, some 30% to 40% of cardiovascular deaths occur between 35 and 64 years of age. The prence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes and rheumatic heart disease ranges from 1.3 to 4.6 million, with an annual incidence of 4,91,600“1.8 million.
ST2 is ELISA based test which is a US FDA approved and was included in 2013 ACC/AHA Guidelines for The Management of Heart Failure. It has been extensively uated with more than 100 peer-reviewed articles and scientific posters studying more than 35,000 patients. So far, SRL Diagnostics has collected 100 samples for to help doctors manage heart failure Dr. Das further added.
The American College of Cardiology Foundation/American Heart Association Task Force jointly released its expanded clinical practice guideline for the management of patients with heart failure and has identified ST2 not only predictive of hospitalization and death in patients with HF [heart failure] but also additive to natriuretic peptide levels in its prognostic value.
SRL consistently follows the best of National and International Quality protocols, thereby ensuring accuracy of every test report.